Know Cancer

forgot password

A Phase I, Open-Label, Study of the Safety, Tolerability and Pharmacokinetics of Pazopanib in Combination With Paclitaxel on a Weekly Schedule for 3 Consecutive Wks, Paclitaxel & Carboplatin on an Every 21 Days Schedule and Lapatinib & Paclitaxel on a Weekly Schedule for 3 Consecutive Weeks

Phase 1
18 Years
Not Enrolling
Solid Tumor Cancer, Neoplasms, Breast

Thank you

Trial Information

A Phase I, Open-Label, Study of the Safety, Tolerability and Pharmacokinetics of Pazopanib in Combination With Paclitaxel on a Weekly Schedule for 3 Consecutive Wks, Paclitaxel & Carboplatin on an Every 21 Days Schedule and Lapatinib & Paclitaxel on a Weekly Schedule for 3 Consecutive Weeks

Inclusion Criteria

Inclusion criteria:

- Confirmed diagnosis of cancer, except cervical cancer

- Eastern Cooperative Oncology Group performance Status of 0 or 1

- Peripheral neuropathy of Grade 1 or less

- Adequate bone marrow function (absolute neutrophils, platelets and hemoglobin levels
as per protocol)

- Adequate renal function as per protocol

- Urine creatinine ratio as per protocol

- Adequate hepatic function as per protocol

- Coagulation tests as per protocol

- Male of female at least 18 years of age

- A woman is eligible to enter and participate in the study if she is of:

- Non-childbearing potential (i.e., physiologically incapable of becoming pregnant),
including any woman who:

- Has had a hysterectomy,

- Has had a bilateral oophorectomy (ovariectomy),

- Has had a bilateral tubal ligation,

- Is post-menopausal (total cessation of menses for at least 1 year)

- Childbearing potential, has a negative serum or urine pregnancy test at screening,
and agrees to one of the following:

- An intrauterine device (IUD) with a documented failure rate of less than 1% per year.

- Vasectomized partner who is sterile prior to the patient's entry and is the sole
sexual partner for that woman.

- Complete abstinence from sexual intercourse for 14 days before exposure to
investigation product, throughout the clinical trial, and for at least 21 days after
the last dose of investigational product.

- Double-barrier contraception defined as condom with spermicidal jelly, foam,
suppository, or film; OR male condom and diaphragm.

- Predicted life expectancy of at least 12 weeks

- Written informed consent

- Able to swallow and retain oral medications.

Exclusion criteria:

- No more than 3 prior lines of cytotoxic chemotherapy for metastatic disease are

- No major surgery, nor cytotoxic chemotherapy, investigational agents, or radiotherapy
within the last 28 days and subject must have recovered fully from whatever their
last treatment was at the time of enrollment.

- Women who are pregnant or breast feeding are not eligible to enroll.

- Cannot have poorly controlled hypertension.

- Cannot have corrected QT (QTc) prolongation

- Cannot have Class III or IV heart failure as defined by the New York Heart
Association functional classification system.

- Cannot have arterial or venous thrombi (including cerebrovascular accident),
myocardial infarction, admission for unstable angina, cardiac angioplasty, or
stenting within the last 3 months.

- Cannot use of therapeutic warfarin.

- Cannot have history of bleeding (hemoptysis, hematuria, GI blood loss, epistaxis, or
others with greater than Grade 1 according to CTC Criteria) within six weeks prior to
beginning therapy or any clinical indications of current active bleeding or bleeding

- Cannot have history or clinical evidence of CNS metastases or leptomeningeal
carcinomatosis, except for individuals who have previously treated CNS metastases,
are asymptomatic, and have had no requirement for steroids or anti-seizure medication
for 2 months prior to beginning study treatment.

- Cannot have any serious and/or unstable pre-existing medical, psychiatric, or other
condition (including laboratory abnormalities) that could interfere with patient
safety or obtaining consent.

- Cannot have history of malabsorption syndrome, disease significantly affecting
gastrointestinal function or major resection of the stomach or small bowel that could
affect absorption, distribution, metabolism or excretion of pazopanib, paclitaxel, or
carboplatin. Has any unresolved bowel obstruction or diarrhea. Has clinically
significant gastrointestinal abnormalities that may increase the risk for GI bleeding
including, but not limited to:

- active peptic ulcer disease,

- known intraluminal metastatic lesion(s) with suspected bleeding,

- inflammatory bowel disease including ulcerative colitis, or other GI conditions
with increased risk of perforation,

- history of abdominal fistula, GI perforation, or intra-abdominal abscess within
28 days prior to beginning study treatment.

- Subject must not have psychological, familial, sociological, or geographical
conditions that do not permit compliance with the protocol.

- Subject must not take any specifically prohibited medication specified in the
protocol during the study or requires any of these medications during treatment with

- Subject must not have clinical history, current alcohol or illicit drug use which, in
the judgment of the Investigator, would interfere with the patient's ability to
comply with the dosing schedule and protocol-specified evaluations.

- Subject must not be allergic to either TAXOL or PARAPLATIN, or any other taxane or
platinum containing compound.

- Subject must not have a current diagnosis of cervical cancer.

- Subject must not have known endobronchial metastasis or involvement of large
pulmonary vessel(s) by tumor.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Adverse Effects, Laboratory parameters

Outcome Time Frame:

before and after taking the study medications.

Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:



United States: Food and Drug Administration

Study ID:




Start Date:

April 2006

Completion Date:

July 2009

Related Keywords:

  • Solid Tumor Cancer
  • Neoplasms, Breast
  • Pazopanib
  • paclitaxel
  • carboplatin
  • lapatinib
  • Breast Neoplasms
  • Neoplasms



GSK Investigational SiteAkron, Ohio  44304
GSK Investigational SiteGermantown, Tennessee  38138
GSK Investigational SiteEdison, New Jersey  08837